EA201692185A1 - Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина - Google Patents

Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина

Info

Publication number
EA201692185A1
EA201692185A1 EA201692185A EA201692185A EA201692185A1 EA 201692185 A1 EA201692185 A1 EA 201692185A1 EA 201692185 A EA201692185 A EA 201692185A EA 201692185 A EA201692185 A EA 201692185A EA 201692185 A1 EA201692185 A1 EA 201692185A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bis
compound
procarament
hexandile
prolina
Prior art date
Application number
EA201692185A
Other languages
English (en)
Other versions
EA032129B1 (ru
Inventor
Алексис Дени
Оливье Мирге
Жером Тум
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of EA201692185A1 publication Critical patent/EA201692185A1/ru
Publication of EA032129B1 publication Critical patent/EA032129B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Настоящее изобретение относится к соединению (2R,2'R)-бис(((((тетрагидро-2Н-пиран-4-ил)окси)карбонил)окси)метил)-1,1'-адипоилбис(пирролидин-2-карбоксилат), к содержащим это соединение фармацевтическим композициям и применению этого соединения для лечения заболеваний или расстройств, где деплеция сывороточного амилоидного Р-компонента (SAP) может быть благоприятной, включая амилоидоз, болезнь Альцгеймера, сахарный диабет 2 типа и остеоартрит.
EA201692185A 2014-04-29 2015-04-27 Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина EA032129B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1407506.3A GB201407506D0 (en) 2014-04-29 2014-04-29 Novel compound
PCT/EP2015/058998 WO2015165833A1 (en) 2014-04-29 2015-04-27 A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Publications (2)

Publication Number Publication Date
EA201692185A1 true EA201692185A1 (ru) 2017-06-30
EA032129B1 EA032129B1 (ru) 2019-04-30

Family

ID=50972033

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692185A EA032129B1 (ru) 2014-04-29 2015-04-27 Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина

Country Status (26)

Country Link
US (3) US9701668B2 (ru)
EP (1) EP3137457B1 (ru)
JP (1) JP6445046B2 (ru)
KR (1) KR20160145617A (ru)
CN (1) CN106459016B (ru)
AR (1) AR100204A1 (ru)
AU (1) AU2015252184B2 (ru)
BR (1) BR112016025129A2 (ru)
CA (1) CA2947060C (ru)
CL (1) CL2016002721A1 (ru)
CR (1) CR20160508A (ru)
DO (1) DOP2016000292A (ru)
EA (1) EA032129B1 (ru)
ES (1) ES2731253T3 (ru)
GB (1) GB201407506D0 (ru)
IL (2) IL248249A0 (ru)
MA (1) MA39406B1 (ru)
MX (1) MX2016014246A (ru)
MY (1) MY191088A (ru)
PE (1) PE20161558A1 (ru)
PH (1) PH12016502006A1 (ru)
SG (1) SG11201608371RA (ru)
TW (1) TWI676624B (ru)
UA (1) UA119871C2 (ru)
UY (1) UY36098A (ru)
WO (1) WO2015165833A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201518950D0 (en) * 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE224366T1 (de) 1997-10-31 2002-10-15 Hoffmann La Roche D-prolinderivate
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
EP1636240A1 (en) 2003-06-05 2006-03-22 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
KR20080004571A (ko) 2005-04-12 2008-01-09 메이지 세이카 가부시키가이샤 2-티오에테닐 카바페넴 유도체
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Also Published As

Publication number Publication date
KR20160145617A (ko) 2016-12-20
WO2015165833A1 (en) 2015-11-05
AR100204A1 (es) 2016-09-21
UA119871C2 (uk) 2019-08-27
TWI676624B (zh) 2019-11-11
PE20161558A1 (es) 2017-01-06
EA032129B1 (ru) 2019-04-30
PH12016502006B1 (en) 2016-12-19
US10597385B2 (en) 2020-03-24
MX2016014246A (es) 2017-02-06
US9701668B2 (en) 2017-07-11
JP6445046B2 (ja) 2018-12-26
US20170267665A1 (en) 2017-09-21
CR20160508A (es) 2017-03-10
BR112016025129A2 (pt) 2017-08-15
AU2015252184B2 (en) 2017-11-02
IL279120A (en) 2021-01-31
EP3137457B1 (en) 2019-04-17
CA2947060A1 (en) 2015-11-05
GB201407506D0 (en) 2014-06-11
CN106459016B (zh) 2019-11-01
CL2016002721A1 (es) 2017-01-20
MA39406B1 (fr) 2018-04-30
CA2947060C (en) 2023-09-26
ES2731253T3 (es) 2019-11-14
DOP2016000292A (es) 2017-11-15
AU2015252184A1 (en) 2016-10-27
MA39406A1 (fr) 2017-07-31
SG11201608371RA (en) 2016-11-29
US9873686B2 (en) 2018-01-23
EP3137457A1 (en) 2017-03-08
UY36098A (es) 2015-11-30
MY191088A (en) 2022-05-30
JP2017514829A (ja) 2017-06-08
US20160075694A1 (en) 2016-03-17
IL248249A0 (en) 2016-11-30
CN106459016A (zh) 2017-02-22
PH12016502006A1 (en) 2016-12-19
TW201625598A (zh) 2016-07-16
US20180099955A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201792047A1 (ru) Новые соединения
EA201792421A1 (ru) Амидозамещенные производные циклогексана
EA202090871A1 (ru) Ингибирование убиквитин-специфической пептидазы 30
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
BR112015019412A2 (pt) inibidores de bace1
EA201990400A1 (ru) Соединения и композиции и их применение
CL2016002510A1 (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano [3,4-d][1,3] tiazin-8a(8h)-il-1,3-tiazol-4-ilamidas.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
EA202090414A1 (ru) Соединения и их применение
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
EA201992272A1 (ru) Ацилированное инсулиновое соединение
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201501175A1 (ru) Новые соединения для лечения злокачественного новообразования
EA201691160A1 (ru) Антагонисты s1p3
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201692185A1 (ru) Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TM